Amyloid beta and Alzheimer's Disease: The role of neprilysin-2 in amyloid-beta clearance

Frontiers in Aging Neuroscience

Volumn 6, Issue JUL, 2014, Pages

  Marr, Robert ^a   Hafez, Daniel ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Alzheimer's disease; Amyloid hypothesis; Amyloid beta degradation; Clearance; NEP; NEP2; Neprilysin; Neprilysin 2

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; NEPRILYSIN 2; PHOSPHORAMIDON; PROTEINASE; THIORPHAN; UNCLASSIFIED DRUG; BAPINEUZUMAB; BETA SECRETASE 1; GAMMA SECRETASE; METALLOPROTEINASE; PRESENILIN 1; PRESENILIN 2; SOLANEZUMAB;

ALZHEIMER DISEASE; ARTICLE; BRAIN; HUMAN; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; AGING; ALTERNATIVE RNA SPLICING; BRAIN LEVEL; DISEASE COURSE; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; MICROGLIA; NERVE CELL PLASTICITY; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW;

EID: 84904677189     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00187     Document Type: Article

References (105)

1. Abramowski, D., Wiederhold, K.H., Furrer, U., Jaton, A.L., Neuenschwander, A., Runser, M.J., Danner, S., Reichwald, J., Ammaturo, D., Staab, D., Stoeckli, M., Rueeger, H., Neumann, U., and Staufenbiel, M. (2008). Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 327, 411-424.
2. Apelt, J., Ach, K., and Schliebs, R. (2003). Aging-related down-regulation of neprilysin, a putative betaamyloid- degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. Neurosci Lett 339, 183-186.
3. Bales, K.R., Verina, T., Cummins, D.J., Du, Y., Dodel, R.C., Saura, J., Fishman, C.E., Delong, C.A., Piccardo, P., Petegnief, V., Ghetti, B., and Paul, S.M. (1999). Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 96, 15233-15238.
4. Barberger-Gateau, P., Raffaitin, C., Letenneur, L., Berr, C., Tzourio, C., Dartigues, J.F., and Alperovitch, A. (2007). Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 69, 1921-1930.
5. Bateman, R.J., Munsell, L.Y., Morris, J.C., Swarm, R., Yarasheski, K.E., and Holtzman, D.M. (2006). Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12, 856-861.
6. Belinson, H., Kariv-Inbal, Z., Kayed, R., Masliah, E., and Michaelson, D.M. (2010). Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-beta resulting in neurodegeneration. J Alzheimers Dis 22, 959-970.
7. Bennett, D.A., Schneider, J.A., Tang, Y., Arnold, S.E., and Wilson, R.S. (2006). The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol 5, 406-412.
8. Bennett, D.A., Schneider, J.A., Wilson, R.S., Bienias, J.L., Berry-Kravis, E., and Arnold, S.E. (2005). Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J Neurol Neurosurg Psychiatry 76, 1194-1199.
9. Bennett, D.A., Wilson, R.S., Schneider, J.A., Evans, D.A., Aggarwal, N.T., Arnold, S.E., Cochran, E.J., Berry-Kravis, E., and Bienias, J.L. (2003). Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 60, 246-252.
10. Blennow, K., Hampel, H., Weiner, M., and Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
11. Bonvouloir, N., Lemieux, N., Crine, P., Boileau, G., and Desgroseillers, L. (2001). Molecular cloning, tissue distribution, and chromosomal localization of MMEL2, a gene coding for a novel human member of the neutral endopeptidase-24.11 family. DNA Cell Biol 20, 493-498.
12. Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10, 333-344.
13. Caccamo, A., Oddo, S., Sugarman, M.C., Akbari, Y., and Laferla, F.M. (2005). Age- and regiondependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 26, 645-654.
14. Carpentier, M., Guillemette, C., Bailey, J.L., Boileau, G., Jeannotte, L., Desgroseillers, L., and Charron, J. (2004). Reduced fertility in male mice deficient in the zinc metallopeptidase NL1. Mol Cell Biol 24, 4428-4437.
15. Chang, M., Jonsson, P.V., Snaedal, J., Bjornsson, S., Saczynski, J.S., Aspelund, T., Eiriksdottir, G., Jonsdottir, M.K., Lopez, O.L., Harris, T.B., Gudnason, V., and Launer, L.J. (2010). The effect of midlife physical activity on cognitive function among older adults: AGES--Reykjavik Study. J Gerontol A Biol Sci Med Sci 65, 1369-1374.
16. Cheng, I.H., Palop, J.J., Esposito, L.A., Bien-Ly, N., Yan, F., and Mucke, L. (2004). Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med 10, 1190-1192.
17. Clements, A., Allsop, D., Walsh, D.M., and Williams, C.H. (1996). Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease. J Neurochem 66, 740-747.
18. Clements, W.D., Halliday, M.I., Mccaigue, M.D., Barclay, R.G., and Rowlands, B.J. (1993). Effects of extrahepatic obstructive jaundice on Kupffer cell clearance capacity. Arch Surg 128, 200-204; discussion 204-205.
19. Courtney, E., Kornfeld, S., Janitz, K., and Janitz, M. (2010). Transcriptome profiling in neurodegenerative disease. J Neurosci Methods 193, 189-202.
20. Dodart, J.C., Marr, R.A., Koistinaho, M., Gregersen, B.M., Malkani, S., Verma, I.M., and Paul, S.M. (2005). Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 102, 1211-1216.
21. Dolev, I., and Michaelson, D.M. (2004). A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc Natl Acad Sci U S A 101, 13909-13914.
22. Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P.S., Siemers, E., Liu-Seifert, H., Mohs, R., Alzheimer's Disease Cooperative Study Steering, C., and Solanezumab Study, G. (2014). Phase 3 trials of solanezumab for mildto- moderate Alzheimer's disease. N Engl J Med 370, 311-321.
23. Facchinetti, P., Rose, C., Schwartz, J.C., and Ouimet, T. (2003). Ontogeny, regional and cellular distribution of the novel metalloprotease neprilysin 2 in the rat: a comparison with neprilysin and endothelin-converting enzyme-1. Neuroscience 118, 627-639.
24. Fagan, A.M., Watson, M., Parsadanian, M., Bales, K.R., Paul, S.M., and Holtzman, D.M. (2002). Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 9, 305-318.
25. Farlow, M., Arnold, S.E., Van Dyck, C.H., Aisen, P.S., Snider, B.J., Porsteinsson, A.P., Friedrich, S., Dean, R.A., Gonzales, C., Sethuraman, G., Demattos, R.B., Mohs, R., Paul, S.M., and Siemers, E.R. (2012). Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 8, 261-271.
26. Ghaddar, G., Ruchon, A.F., Carpentier, M., Marcinkiewicz, M., Seidah, N.G., Crine, P., Desgroseillers, L., and Boileau, G. (2000). Molecular cloning and biochemical characterization of a new mouse testis soluble-zinc-metallopeptidase of the neprilysin family. Biochem J 347, 419-429.
27. Goedert, M., and Spillantini, M.G. (2006). A century of Alzheimer's disease. Science 314, 777-781.
28. Griciuc, A., Serrano-Pozo, A., Parrado, A.R., Lesinski, A.N., Asselin, C.N., Mullin, K., Hooli, B., Choi, S.H., Hyman, B.T., and Tanzi, R.E. (2013). Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631-643.
29. Hafez, D., Huang, J.Y., Huynh, A.M., Valtierra, S., Rockenstein, E., Bruno, A.M., Lu, B., Desgroseillers, L., Masliah, E., and Marr, R.A. (2011). Neprilysin-2 is an important beta-amyloid degrading enzyme. Am J Pathol 178, 306-312.
30. Hanson, L.R., Hafez, D., Svitak, A.L., Burns, R.B., Li, X., Frey, W.H., 2nd, and Marr, R.A. (2010). Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice. J Mol Neurosci 43, 424-427.
31. Hashimoto, T., Serrano-Pozo, A., Hori, Y., Adams, K.W., Takeda, S., Banerji, A.O., Mitani, A., Joyner, D., Thyssen, D.H., Bacskai, B.J., Frosch, M.P., Spires-Jones, T.L., Finn, M.B., Holtzman, D.M., and Hyman, B.T. (2012). Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci 32, 15181-15192.
32. Holtzman, D.M., Bales, K.R., Tenkova, T., Fagan, A.M., Parsadanian, M., Sartorius, L.J., Mackey, B., Olney, J., Mckeel, D., Wozniak, D., and Paul, S.M. (2000). Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 97, 2892-2897.
33. Howell, S., Nalbantoglu, J., and Crine, P. (1995). Neutral endopeptidase can hydrolyze beta-amyloid(1- 40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 16, 647-652.
34. Huang, J.Y., Bruno, A.M., Patel, C.A., Huynh, A.M., Philibert, K.D., Glucksman, M.J., and Marr, R.A. (2008). Human membrane metallo-endopeptidase-like protein degrades both beta-amyloid 42 and beta-amyloid 40. Neuroscience 155, 258-262.
35. Huang, J.Y., Hafez, D.M., James, B.D., Bennett, D.A., and Marr, R.A. (2012). Altered NEP2 Expression and Activity in Mild Cognitive Impairment and Alzheimer's Disease. J Alzheimers Dis 28, 433- 441.
36. Ikeda, K., Emoto, N., Raharjo, S.B., Nurhantari, Y., Saiki, K., Yokoyama, M., and Matsuo, M. (1999). Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides. J Biol Chem 274, 32469-32477.
37. Iwata, N., Takaki, Y., Fukami, S., Tsubuki, S., and Saido, T.C. (2002). Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 70, 493-500.
38. Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N.P., Gerard, C., Hama, E., Lee, H.J., and Saido, T.C. (2001). Metabolic regulation of brain Abeta by neprilysin. Science 292, 1550- 1552.
39. Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.J., Hama, E., Sekine-Aizawa, Y., and Saido, T.C. (2000). Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6, 143-150.
40. Iwatsubo, T. (1998). Abeta42, presenilins, and Alzheimer's disease. Neurobiol Aging 19, S11-13.
41. Jarrett, J.T., and Lansbury, P.T., Jr. (1993). Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058.
42. Jiang, Q., Lee, C.Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T.M., Collins, J.L., Richardson, J.C., Smith, J.D., Comery, T.A., Riddell, D., Holtzman, D.M., Tontonoz, P., and Landreth, G.E. (2008). ApoE promotes the proteolytic degradation of Abeta. Neuron 58, 681-693.
43. Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R.R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O.A., Jonsson, E.G., Palotie, A., Behrens, T.W., Magnusson, O.T., Kong, A., Thorsteinsdottir, U., Watts, R.J., and Stefansson, K. (2012). A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99.
44. Kaden, D., Harmeier, A., Weise, C., Munter, L.M., Althoff, V., Rost, B.R., Hildebrand, P.W., Schmitz, D., Schaefer, M., Lurz, R., Skodda, S., Yamamoto, R., Arlt, S., Finckh, U., and Multhaup, G. (2012). Novel APP/Abeta mutation K16N produces highly toxic heteromeric Abeta oligomers. EMBO Mol Med 4, 647-659.
45. Kerr, M.A., and Kenny, A.J. (1974a). The molecular weight and properties of a neutral metalloendopeptidase from rabbit kidney brush border. Biochem J 137, 489-495.
46. Kerr, M.A., and Kenny, A.J. (1974b). The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 137, 477-488.
47. Kim, W.S., Li, H., Ruberu, K., Chan, S., Elliott, D.A., Low, J.K., Cheng, D., Karl, T., and Garner, B. (2013). Deletion of Abca7 increases cerebral amyloid-beta accumulation in the J20 mouse model of Alzheimer's disease. J Neurosci 33, 4387-4394.
48. Kline, A. (2012). Apolipoprotein E, amyloid-ss clearance and therapeutic opportunities in Alzheimer's disease. Alzheimers Res Ther 4, 32.
49. Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K.R., and Paul, S.M. (2004). Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10, 719-726.
50. Korf, E.S., White, L.R., Scheltens, P., and Launer, L.J. (2004). Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension 44, 29-34.
51. Leuner, K., Schulz, K., Schutt, T., Pantel, J., Prvulovic, D., Rhein, V., Savaskan, E., Czech, C., Eckert, A., and Muller, W.E. (2012). Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes. Mol Neurobiol 46, 194-204.
52. Lippa, C.F., Saunders, A.M., Smith, T.W., Swearer, J.M., Drachman, D.A., Ghetti, B., Nee, L., Pulaski- Salo, D., Dickson, D., Robitaille, Y., Bergeron, C., Crain, B., Benson, M.D., Farlow, M., Hyman, B.T., George-Hyslop, S.P., Roses, A.D., and Pollen, D.A. (1996). Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology 46, 406-412.
53. Madani, R., Poirier, R., Wolfer, D.P., Welzl, H., Groscurth, P., Lipp, H.P., Lu, B., El Mouedden, M., Mercken, M., Nitsch, R.M., and Mohajeri, M.H. (2006). Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J Neurosci Res 84, 1871- 1878.
54. Manelli, A.M., Stine, W.B., Van Eldik, L.J., and Ladu, M.J. (2004). ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci 23, 235-246.
55. Mapstone, M., Cheema, A.K., Fiandaca, M.S., Zhong, X., Mhyre, T.R., Macarthur, L.H., Hall, W.J., Fisher, S.G., Peterson, D.R., Haley, J.M., Nazar, M.D., Rich, S.A., Berlau, D.J., Peltz, C.B., Tan, M.T., Kawas, C.H., and Federoff, H.J. (2014). Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med.
56. Marr, R. (2013). Neprilysin-2. In Handbook of Proteolytic Enzymes. Oxford: Academic Press.
57. Marr, R.A., Rockenstein, E., Mukherjee, A., Kindy, M.S., Hersh, L.B., Gage, F.H., Verma, I.M., and Masliah, E. (2003). Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 23, 1992-1996.
58. Marr, R.A., and Spencer, B.J. (2010). NEP-like Endopeptidases and Alzheimer's Disease. Curr Alzheimer Res 7, 223-229.
59. Maruyama, M., Higuchi, M., Takaki, Y., Matsuba, Y., Tanji, H., Nemoto, M., Tomita, N., Matsui, T., Iwata, N., Mizukami, H., Muramatsu, S., Ozawa, K., Saido, T.C., Arai, H., and Sasaki, H. (2005). Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann Neurol 57, 832- 842.
60. Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C., Yarasheski, K.E., and Bateman, R.J. (2010). Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
61. Mcghee, D.J., Ritchie, C.W., Thompson, P.A., Wright, D.E., Zajicek, J.P., and Counsell, C.E. (2014). A systematic review of biomarkers for disease progression in Alzheimer's disease. PLoS One 9, e88854.
62. Miners, J.S., Baig, S., Tayler, H., Kehoe, P.G., and Love, S. (2009). Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol 68, 902-914.
63. Miners, J.S., Barua, N., Kehoe, P.G., Gill, S., and Love, S. (2011a). Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 70, 944-959.
64. Miners, J.S., Morris, S., Love, S., and Kehoe, P.G. (2011b). Accumulation of insoluble amyloid-beta in down's syndrome is associated with increased BACE-1 and neprilysin activities. J Alzheimers Dis 23, 101-108.
65. Miners, J.S., Van Helmond, Z., Kehoe, P.G., and Love, S. (2010). Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol 20, 794-802.
66. Morley, J.E., Farr, S.A., Banks, W.A., Johnson, S.N., Yamada, K.A., and Xu, L. (2010). A physiological role for amyloid-beta protein:enhancement of learning and memory. J Alzheimers Dis 19, 441- 449.
67. Nalivaeva, N.N., Beckett, C., Belyaev, N.D., and Turner, A.J. (2012). Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? J Neurochem 120 Suppl 1, 167-185.
68. Ngandu, T., Von Strauss, E., Helkala, E.L., Winblad, B., Nissinen, A., Tuomilehto, J., Soininen, H., and Kivipelto, M. (2007). Education and dementia: what lies behind the association? Neurology 69, 1442-1450.
69. Nilsberth, C., Westlind-Danielsson, A., Eckman, C.B., Condron, M.M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D.B., Younkin, S.G., Naslund, J., and Lannfelt, L. (2001). The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 4, 887-893.
70. Nisemblat, Y., Belinson, H., Dolev, I., and Michaelson, D.M. (2008). Activation of the amyloid cascade by intracerebroventricular injection of the protease inhibitor phosphoramidon. Neurodegener Dis 5, 166-169.
71. Ouimet, T., Facchinetti, P., Rose, C., Bonhomme, M.C., Gros, C., and Schwartz, J.C. (2000). Neprilysin II: A putative novel metalloprotease and its isoforms in CNS and testis. Biochem Biophys Res Commun 271, 565-570.
72. Pimplikar, S.W. (2009). Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 41, 1261-1268.
73. Prasher, V.P., Farrer, M.J., Kessling, A.M., Fisher, E.M., West, R.J., Barber, P.C., and Butler, A.C. (1998). Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 43, 380-383.
74. Puzzo, D., Privitera, L., Leznik, E., Fa, M., Staniszewski, A., Palmeri, A., and Arancio, O. (2008). Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28, 14537-14545.
75. Puzzo, D., Privitera, L., and Palmeri, A. (2012). Hormetic effect of amyloid-beta peptide in synaptic plasticity and memory. Neurobiol Aging 33, 1484 e1415-1424.
76. Raharjo, S.B., Emoto, N., Ikeda, K., Sato, R., Yokoyama, M., and Matsuo, M. (2001). Alternative splicing regulates the endoplasmic reticulum localization or secretion of soluble secreted endopeptidase. J Biol Chem 276, 25612-25620.
77. Reijmer, Y.D., Van Den Berg, E., Dekker, J.M., Nijpels, G., Stehouwer, C.D., Kappelle, L.J., and Biessels, G.J. (2012). Development of vascular risk factors over 15 years in relation to cognition: the Hoorn Study. J Am Geriatr Soc 60, 1426-1433.
78. Reilly, C.E. (2001). Neprilysin content is reduced in Alzheimer brain areas. J Neurol 248, 159-160.
79. Reitz, C., Jun, G., Naj, A., Rajbhandary, R., Vardarajan, B.N., Wang, L.S., Valladares, O., Lin, C.F., Larson, E.B., Graff-Radford, N.R., Evans, D., De Jager, P.L., Crane, P.K., Buxbaum, J.D., Murrell, J.R., Raj, T., Ertekin-Taner, N., Logue, M., Baldwin, C.T., Green, R.C., Barnes, L.L., Cantwell, L.B., Fallin, M.D., Go, R.C., Griffith, P., Obisesan, T.O., Manly, J.J., Lunetta, K.L., Kamboh, M.I., Lopez, O.L., Bennett, D.A., Hendrie, H., Hall, K.S., Goate, A.M., Byrd, G.S., Kukull, W.A., Foroud, T.M., Haines, J.L., Farrer, L.A., Pericak-Vance, M.A., Schellenberg, G.D., Mayeux, R., and Alzheimer Disease Genetics, C. (2013). Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4,and the risk of late-onset Alzheimer disease in African Americans. JAMA 309, 1483-1492.
80. Roberson, E.D., and Mucke, L. (2006). 100 years and counting: prospects for defeating Alzheimer's disease. Science 314, 781-784.
81. Roher, A.E., Cribbs, D.H., Kim, R.C., Maarouf, C.L., Whiteside, C.M., Kokjohn, T.A., Daugs, I.D., Head, E., Liebsack, C., Serrano, G., Belden, C., Sabbagh, M.N., and Beach, T.G. (2013). Bapineuzumab alters abeta composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. PLoS One 8, e59735.
82. Rose, C., Voisin, S., Gros, C., Schwartz, J.C., and Ouimet, T. (2002). Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin. Biochem J 363, 697-705.
83. Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerriere, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., Dubas, F., Frebourg, T., and Campion, D. (2006). APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38, 24-26.
84. Rusanen, M., Kivipelto, M., Quesenberry, C.P., Jr., Zhou, J., and Whitmer, R.A. (2011). Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med 171, 333-339.
85. Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L.S., Porsteinsson, A.P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I.C., Liu, E., Grundman, M., Yuen, E., Black, R., Brashear, H.R., Bapineuzumab, and Clinical Trial, I. (2014). Two phase 3 trials of bapineuzumab in mildto- moderate Alzheimer's disease. N Engl J Med 370, 322-333.
86. Salloway, S., Sperling, R., Gilman, S., Fox, N.C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L.S., Doody, R., Van Dyck, C.H., Mulnard, R., Barakos, J., Gregg, K.M., Liu, E., Lieberburg, I., Schenk, D., Black, R., Grundman, M., and Bapineuzumab 201 Clinical Trial, I. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.
87. Shibata, M., Yamada, S., Kumar, S.R., Calero, M., Bading, J., Frangione, B., Holtzman, D.M., Miller, C.A., Strickland, D.K., Ghiso, J., and Zlokovic, B.V. (2000). Clearance of Alzheimer's amyloidss( 1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499.
88. Shirotani, K., Tsubuki, S., Iwata, N., Takaki, Y., Harigaya, W., Maruyama, K., Kiryu-Seo, S., Kiyama, H., Iwata, H., Tomita, T., Iwatsubo, T., and Saido, T.C. (2001). Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem 276, 21895-21901.
89. Sorrentino, P., Iuliano, A., Polverino, A., Jacini, F., and Sorrentino, G. (2014). The dark sides of amyloid in Alzheimer's disease pathogenesis. FEBS Lett 588, 641-652.
90. Tang, Y., Gilbert, D.L., Glauser, T.A., Hershey, A.D., and Sharp, F.R. (2005). Blood gene expression profiling of neurologic diseases: a pilot microarray study. Arch Neurol 62, 210-215.
91. Tanzi, R.E. (2012). The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2.
92. Tolppanen, A.M., Lavikainen, P., Solomon, A., Kivipelto, M., Uusitupa, M., Soininen, H., and Hartikainen, S. (2013). History of medically treated diabetes and risk of Alzheimer disease in a nationwide case-control study. Diabetes Care 36, 2015-2019.
93. Tsubuki, S., Takaki, Y., and Saido, T.C. (2003). Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 361, 1957- 1958.
94. Turner, A.J., Isaac, R.E., and Coates, D. (2001). The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23, 261-269.
95. Van Vliet, P., Van De Water, W., De Craen, A.J., and Westendorp, R.G. (2009). The influence of age on the association between cholesterol and cognitive function. Exp Gerontol 44, 112-122.
96. Virta, J.J., Heikkila, K., Perola, M., Koskenvuo, M., Raiha, I., Rinne, J.O., and Kaprio, J. (2013). Midlife cardiovascular risk factors and late cognitive impairment. Eur J Epidemiol 28, 405-416.
97. Voisin, S., Rognan, D., Gros, C., and Ouimet, T. (2004). A three-dimensional model of the neprilysin 2 active site based on the X-ray structure of neprilysin. Identification of residues involved in substrate hydrolysis and inhibitor binding of neprilysin 2. J Biol Chem 279, 46172-46181.
98. Walsh, D.M., Minogue, A.M., Sala Frigerio, C., Fadeeva, J.V., Wasco, W., and Selkoe, D.J. (2007). The APP family of proteins: similarities and differences. Biochem Soc Trans 35, 416-420.
99. Wang, D.S., Lipton, R.B., Katz, M.J., Davies, P., Buschke, H., Kuslansky, G., Verghese, J., Younkin, S.G., Eckman, C., and Dickson, D.W. (2005). Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol 64, 378-385.
100. Wang, S., Wang, R., Chen, L., Bennett, D.A., Dickson, D.W., and Wang, D.S. (2010). Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J Neurochem 115, 47-57.
101. Whyteside, A.R., and Turner, A.J. (2008). Human neprilysin-2 (NEP2) and NEP display distinct subcellular localisations and substrate preferences. FEBS Lett 582, 2382-2386.
102. Wisniewski, K.E., Dalton, A.J., Mclachlan, C., Wen, G.Y., and Wisniewski, H.M. (1985). Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 35, 957-961.
103. Wu, Y., Le, W., and Jankovic, J. (2011). Preclinical biomarkers of Parkinson disease. Arch Neurol 68, 22-30.
104. Yasojima, K., Akiyama, H., Mcgeer, E.G., and Mcgeer, P.L. (2001a). Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett 297, 97-100.
105. Yasojima, K., Mcgeer, E.G., and Mcgeer, P.L. (2001b). Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 919, 115-121.